Table 2.
Demographic data, underlying medical conditions, clinical manifestations, and laboratory findings of patients with pneumonia caused by SARS-CoV-2.
| Huang et al.13 (n = 41) | Chen et al.12 (n = 99) | Wang et al.14 (n = 138) | Liu et al.23 (n = 17) | Guan et al.11 (n = 173) | |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 30 (73.2) | 67 (67.7) | 75 (54.3) | 10 (58.8) | 100 (57.8) |
| Female | 11 (26.8) | 32 (32.3) | 63 (45.7) | 7 (41.2) | 73 (42.2) |
| Age, year | 49.3 (13.0) | 52.7 (46.7) | 55.3 (19.9) | 54.3 (29.9) | 52.3 (19.2) |
| Smoking | 3 (7.3) | NA | NA | 2 (11.8) | 38 (22.0) |
| Comorbidities | |||||
| Diabetes mellitus | 8 (19.5) | NA | 14 (10.1) | 3 (17.6) | 28 (16.2) |
| Hypertension | 6 (14.6) | NA | 43 (31.2) | 6 (35.3) | 41 (23.7) |
| COPD | 1 (2.4) | 1 (1.0) | 4 (2.9) | 3 (17.6) | 6 (3.5) |
| Chronic kidney disease | NA | NA | 4 (2.9) | NA | 3 (1.7) |
| Chronic liver disease | 1 (2.4) | NA | NA | NA | 1 (0.6) |
| Malignancy | 1 (2.4) | 1 (1.0) | 10 (7.2) | NA | 3 (1.7) |
| Presentation | |||||
| Fever | 40 (97.6) | 82 (82.8) | 136 (98.6) | 17 (100.0) | 82 (47.4) |
| Cough | 31 (75.6) | 81 (81.8) | 82 (59.4) | 14 (82.4) | 122 (70.5) |
| Sore throat | NA | 5 (5.1) | 24 (17.4) | 4 (23.5) | 23 (13.3) |
| Dyspnea | 22 (53.7) | 31 (31.3) | 43 (31.2) | 6 (35.3) | 65 (37.6) |
| Myalgia/fatigue | 18 (43.9) | 11 (11.1) | 96 (69.6) | 12 (70.6) | 99 (57.2) |
| Sputum production | 11 (26.8) | NA | 37 (26.8) | 11 (64.7) | 61 (35.3) |
| Headache | 3 (7.3) | 8 (8.1) | 9 (6.5) | 3 (17.6) | 26 (15.0) |
| Diarrhea | 1 (2.4) | 2 (2.0) | 14 (10.1) | 1 (5.9) | 10 (5.8) |
| Nausea or vomiting | NA | 1 (1.0) | 19 (13.8) | 2 (11.8) | 12 (6.9) |
| White blood cell, ×109/L | 6.9 (4.9) | 7.5 (3.6) | 4.7 (2.2) | 4.6 (1.5) | 4.3 (2.5) |
| Neutrophil | 5.7 (4.3) | 5.5 (3.7) | 3.3 (2.2) | 3.3 (2.0) | NA |
| Lymphocyte | 0.8 (0.4) | 0.9 (0.5) | 0.8 (0.4) | 0.9 (0.3) | 0.8 (0.3) |
| Treatment | |||||
| Oxygen therapy | 27 (65.9) | 75 (75.8) | 106 (76.8) | 10 (58.8) | 114 (65.9) |
| Ventilator | 14 (34.1) | 17 (17.2) | 32 (23.2) | 5 (29.4) | 67 (38.7) |
| Renal replacement therapy | 3 (7.3) | 9 (9.1) | 2 (1.4) | NA | 9 (5.2) |
| ECMO | 2 (4.9) | 3 (3.0) | 4 (2.9) | NA | 5 (2.9) |
| Antibiotic therapy | 41 (100.0) | 70 (70.7) | NA | 14 (82.) | 139 (80.3) |
| Antiviral therapy | 39 (95.1) | 75 (75.8) | 124 (89.9) | 11 (64.7) | 80 (46.2) |
| Outcome | |||||
| Discharged | 28 (68.3) | 31 (31.3) | 47 (34.1) | 0 (0.0) | 5 (2.9) |
| Remained hospitalized | 7 (17.1) | 57 (57.6) | 85 (61.6) | 10 (58.) | 154 (89.0) |
| Died | 6 (14.6) | 11 (11.1) | 6 (4.3) | NA | 14 (8.1) |
Data are n (%), n/N (%), and mean (SD).
COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation; NA, not available.